Evotec SE (EVO) Net Income towards Common Stockholders (2020 - 2025)
Evotec SE's (EVO) quarterly Net Income towards Common Stockholders came in at -$100.9 million in Q4 2025, up 51.3% year-on-year from -$66.7 million in Q4 2024, and down 200734.07% quarter-over-quarter from -$50222.6 in Q3 2025.
Evotec SE (EVO) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends
Evotec SE has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$100.9 million for Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$100.9 million, up 51.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$100.9 million (up 51.28% YoY), and the FY2025 annual result was -$120.5 million, up 42.49% from the prior year.
- Net Income towards Common Stockholders came in at -$100.9 million for Q4 2025 at Evotec SE, down from -$50222.6 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $246.3 million in Q4 2021 to a low of -$207.1 million in Q4 2024.
- The 5-year median for Net Income towards Common Stockholders is -$29810.4 (2022), against an average of -$22.1 million.
- Across the five-year window, Net Income towards Common Stockholders surged 9714.16% in 2021 and plunged 229.31% in 2022, its largest moves.
- Evotec SE's Net Income towards Common Stockholders stood at $246.3 million in 2021, then slumped by 172.84% to -$179.4 million in 2022, then jumped by 49.69% to -$90.2 million in 2023, then slumped by 129.5% to -$207.1 million in 2024, then surged by 51.3% to -$100.9 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$100.9 million (Q4 2025), -$50222.6 (Q3 2025), and -$207.1 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Evotec SE | 570.60 Mn | 570.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -100.86 Mn |
| Sep 30, 2025 | -50,222.61 |
| Dec 31, 2024 | -207.09 Mn |
| Sep 30, 2024 | -51,477.94 |
| Dec 31, 2023 | -90.24 Mn |
| Sep 30, 2023 | 42,406.04 |
| Jun 30, 2023 | -22,254.35 |
| Dec 31, 2022 | -179.36 Mn |
| Sep 30, 2022 | 47,666.17 |
| Jun 30, 2022 | -29,810.36 |
| Mar 31, 2022 | -82,202.26 |
| Dec 31, 2021 | 246.25 Mn |
| Sep 30, 2021 | 158,344.09 |
| Jun 30, 2021 | 72,274.35 |
| Mar 31, 2021 | 63,571.06 |
| Dec 31, 2020 | 7.48 Mn |
| Sep 30, 2020 | -1,646.99 |